Drug Profile
LYP18
Alternative Names: LYP18 monoclonal antibodyLatest Information Update: 08 Feb 2000
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Feb 2000 No-Development-Reported for Cancer in USA (Unknown route)
- 24 Apr 1997 Preclinical development for Cancer in USA (Unknown route)